These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 11394505

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
    Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC.
    J Immunother (1991); 2001 May; 24(3):263-271. PubMed ID: 11395643
    [Abstract] [Full Text] [Related]

  • 3. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
    Treon SP, Shima Y, Preffer FI, Doss DS, Ellman L, Schlossman RL, Grossbard ML, Belch AR, Pilarski LM, Anderson KC.
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
    [Abstract] [Full Text] [Related]

  • 4. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.
    Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S.
    Leuk Res; 2006 May; 30(5):625-31. PubMed ID: 16289746
    [Abstract] [Full Text] [Related]

  • 5. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 6. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.
    Haematologica; 2002 Jan 24; 87(1):33-43. PubMed ID: 11801463
    [Abstract] [Full Text] [Related]

  • 7. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG.
    Exp Hematol; 2005 Apr 24; 33(4):452-9. PubMed ID: 15781336
    [Abstract] [Full Text] [Related]

  • 8. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 24; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 9. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
    Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4556-64. PubMed ID: 17671142
    [Abstract] [Full Text] [Related]

  • 10. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.
    Bonavida B.
    Oncogene; 2007 May 28; 26(25):3629-36. PubMed ID: 17530016
    [Abstract] [Full Text] [Related]

  • 11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [Abstract] [Full Text] [Related]

  • 12. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB.
    Clin Cancer Res; 2008 Jul 15; 14(14):4650-7. PubMed ID: 18628480
    [Abstract] [Full Text] [Related]

  • 13. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M, Lin Z, Qiao C, Gen S, Lang X, Li Y, Feng J, Shen B.
    Cancer Lett; 2010 Aug 01; 294(1):66-73. PubMed ID: 20202740
    [Abstract] [Full Text] [Related]

  • 14. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, Martinez-Miguel B, Hernandez-Pando R, González-Bonilla CR, Chinn P, Hanna N, Hariharan K, Jazirehi AR, Bonavida B.
    Clin Cancer Res; 2009 Nov 01; 15(21):6582-94. PubMed ID: 19861448
    [Abstract] [Full Text] [Related]

  • 15. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
    Alas S, Emmanouilides C, Bonavida B.
    Clin Cancer Res; 2001 Mar 01; 7(3):709-23. PubMed ID: 11297268
    [Abstract] [Full Text] [Related]

  • 17. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.
    J Immunother; 2001 Mar 01; 24(3):272-9. PubMed ID: 11394506
    [Abstract] [Full Text] [Related]

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R, Hagenbeek A.
    Eur J Haematol Suppl; 2007 Jan 01; (67):5-14. PubMed ID: 17206982
    [Abstract] [Full Text] [Related]

  • 19. Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.
    Ziller F, Macor P, Bulla R, Sblattero D, Marzari R, Tedesco F.
    Eur J Immunol; 2005 Jul 01; 35(7):2175-83. PubMed ID: 15971270
    [Abstract] [Full Text] [Related]

  • 20. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ.
    Clin Cancer Res; 2008 Mar 01; 14(5):1561-70. PubMed ID: 18316581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.